Cargando…
Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme
Glioblastoma (GBM), a prevalent and malignant brain tumor, poses a challenge in surgical resection due to its invasive nature within the brain parenchyma. CDKN1A (p21, Waf-1), a cyclin-dependent kinase inhibitor, plays a pivotal role in regulating cell growth arrest, terminal differentiation, and ap...
Autores principales: | Cheng, Wen-Yu, Shen, Chiung-Chyi, Liang, Yea-Jiuen, Chiao, Ming-Tsang, Yang, Yi-Chin, Hsieh, Wan-Yu, Lin, Cheng-Hui, Chen, Jun-Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510274/ https://www.ncbi.nlm.nih.gov/pubmed/37730565 http://dx.doi.org/10.1186/s12885-023-11400-5 |
Ejemplares similares
-
Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment
por: Shen, Chiung-Chyi, et al.
Publicado: (2020) -
Luteolin inhibits migration of human glioblastoma U-87 MG and T98G cells through downregulation of Cdc42 expression and PI3K/AKT activity
por: Cheng, Wen-Yu, et al.
Publicado: (2013) -
Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010) -
A Rare Triploid Involving the Coexistence of Glioblastoma Multiforme, Arteriovenous Malformation and Intracranial Aneurysm: Illustrative Case and Literature Review
por: Li, Chi-Ruei, et al.
Publicado: (2023) -
New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab
por: Moustakas, Argirios, et al.
Publicado: (2010)